Literature DB >> 15843495

Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells.

William E Ackerman1, Xiaolan L Zhang, Brad H Rovin, Douglas A Kniss.   

Abstract

Cyclooxygenase (COX) activity increases in the human amnion in the settings of term and idiopathic preterm labor, contributing to the generation of uterotonic prostaglandins (PGs) known to participate in mammalian parturition. Augmented COX activity is highly correlated with increased COX2 (also known as prostaglandin-endoperoxide synthase 2, PTGS2) gene expression. We and others have demonstrated an essential role for nuclear factor kappaB (NFkappaB) in cytokine-driven COX2 expression. Peroxisome proliferator-activated receptor gamma (PPARG), a member of the nuclear hormone receptor superfamily, has been shown to antagonize NFkappaB activation and inflammatory gene expression, including COX2. We hypothesized that PPARG activation might suppress COX2 expression during pregnancy. Using primary amnion and WISH cells, we evaluated the effects of pharmacological (thiazolidinediones) and putative endogenous (15-deoxy-Delta(12,14)-prostaglandin J2, 15d-PGJ2) PPARG ligands on cytokine-induced NFkappaB activation, COX2 expression, and PGE2 production. We observed that COX2 expression and PGE2 production induced by tumor necrosis factor alpha (TNF) were significantly abrogated by 15d-PGJ2. The thiazolidinediones rosiglitazone (ROSI) and troglitazone (TRO) had relatively little effect on cytokine-induced COX2 expression except at high concentrations, at which these agents tended to increase COX2 abundance relative to cells treated with TNF alone. Interestingly, treatment with ROSI, but not TRO, led to augmentation of TNF-stimulated PGE2 production. Mechanistically, we observed that 15d-PGJ2 markedly diminished cytokine-induced activity of the NFkappaB transcription factor, whereas thiazolidinediones had no discernable effect on this system. Our data suggest that pharmacological and endogenous PPARG ligands use both receptor-dependent and -independent mechanisms to influence COX2 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843495      PMCID: PMC1360652          DOI: 10.1095/biolreprod.104.039032

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  54 in total

Review 1.  COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?

Authors:  P R Colville-Nash; D W Gilroy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-06       Impact factor: 3.072

2.  The 15-deoxy-delta(12,14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma (PPARgamma) is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells.

Authors:  K W Marvin; R L Eykholt; J A Keelan; T A Sato; M D Mitchell
Journal:  Placenta       Date:  2000-05       Impact factor: 3.481

3.  Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.

Authors:  K Subbaramaiah; D T Lin; J C Hart; A J Dannenberg
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

4.  NF-kappaB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH).

Authors:  V C Allport; D M Slater; R Newton; P R Bennett
Journal:  Mol Hum Reprod       Date:  2000-06       Impact factor: 4.025

5.  15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats.

Authors:  Y Kawahito; M Kondo; Y Tsubouchi; A Hashiramoto; D Bishop-Bailey; K Inoue; M Kohno; R Yamada; T Hla; H Sano
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

6.  PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation.

Authors:  A Chawla; Y Barak; L Nagy; D Liao; P Tontonoz; R M Evans
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

7.  Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages.

Authors:  A Castrillo; M J Díaz-Guerra; S Hortelano; P Martín-Sanz; L Boscá
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

Authors:  D S Straus; G Pascual; M Li; J S Welch; M Ricote; C H Hsiang; L L Sengchanthalangsy; G Ghosh; C K Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 9.  PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.

Authors:  G J Murphy; J C Holder
Journal:  Trends Pharmacol Sci       Date:  2000-12       Impact factor: 14.819

10.  Blockade NF-kappaB activation prohibits TNF-alpha-induced cyclooxygenase-2 gene expression in ED27 trophoblast-like cells.

Authors:  D A Kniss; B Rovin; R H Fertel; P D Zimmerman
Journal:  Placenta       Date:  2001-01       Impact factor: 3.481

View more
  16 in total

Review 1.  The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome.

Authors:  R Romero; J Espinoza; F Gotsch; J P Kusanovic; L A Friel; O Erez; S Mazaki-Tovi; N G Than; S Hassan; G Tromp
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

Review 2.  Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism.

Authors:  J Davidson; D Rotondo; M T Rizzo; H A Leaver
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  The use of Cox-2 and PPARγ signaling in anti-cancer therapies.

Authors:  Lucia Knopfová; Jan Smarda
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

4.  Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.

Authors:  Anca Nenicu; Yuan Gu; Christina Körbel; Michael D Menger; Matthias W Laschke
Journal:  Br J Pharmacol       Date:  2017-07-06       Impact factor: 8.739

5.  Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.

Authors:  Marilyn L Slovak; Victoria Bedell; Ya-Hsuan Hsu; Dolores B Estrine; Norma J Nowak; Maria L Delioukina; Lawrence M Weiss; David D Smith; Stephen J Forman
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

6.  Inflammatory gene regulatory networks in amnion cells following cytokine stimulation: translational systems approach to modeling human parturition.

Authors:  Ruth Li; William E Ackerman; Taryn L Summerfield; Lianbo Yu; Parul Gulati; Jie Zhang; Kun Huang; Roberto Romero; Douglas A Kniss
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

7.  PPAR γ Regulates Genes Involved in Triacylglycerol Synthesis and Secretion in Mammary Gland Epithelial Cells of Dairy Goats.

Authors:  Hengbo Shi; Jun Luo; Jiangjiang Zhu; Jun Li; Yuting Sun; Xianzi Lin; Liping Zhang; Dawei Yao; Huaiping Shi
Journal:  PPAR Res       Date:  2013-04-17       Impact factor: 4.964

8.  Placental implications of peroxisome proliferator-activated receptors in gestation and parturition.

Authors:  Valerie Borel; Denis Gallot; Geoffroy Marceau; Vincent Sapin; Loïc Blanchon
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Omega-3 Fatty Acids and PPARgamma in Cancer.

Authors:  Iris J Edwards; Joseph T O'Flaherty
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.

Authors:  Bin Xing; Tao Xin; Randy Lee Hunter; Guoying Bing
Journal:  J Neuroinflammation       Date:  2008-01-18       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.